Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03277469 · ClinicalTrials.gov registry record · NA
Optimizing Brachytherapy Application and Delivery With MRI Guidance for Gynecologic Cancer
A NA study of Gynecologic Cancer, sponsored by Dana-Farber Cancer Institute.
- Active
- Registry status
- NA
- Development phase
- 49
- Enrollment target
- 1
- Study location
NCT03277469: Active NA study of Gynecologic Cancer, sponsored by Dana-Farber Cancer Institute.
NCT03277469 is a NA study of Gynecologic Cancer that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 49 participants, below the 764-participant average among 55 other Gynecologic Cancer trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03277469, a NA study of Gynecologic Cancer, is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 49 participants
- Enrollment target
- 1
- Study location
Study Summary
The aim of this study is to develop new tools using magnetic resonance imaging (MRI) that will improve the brachytherapy procedure and treatment for participants with gynecologic cancer.
Primary Outcome
Comparison of brachytherapy treatment parameters for patients treated with or without use of an MR-tracker. V150 is the tumor volume that receives at least 150% of the prescribed radiation dose and is a measure of radiation dose heterogeneity
Conditions Studied
Interventions
- RADIATION Brachytherapy
- DEVICE MRI
- DEVICE MRI Tracker
Study Locations (1)
Massachusetts
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2017-11-13 |
| Est. Completion | 2027-09-15 |
| Phase | NA |
What the registry record for NCT03277469 still lists
NCT03277469 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 49 participants, a relatively small participant target, below the 764-participant average among 55 other Gynecologic Cancer trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Gynecologic Cancer appearing as the primary indexed condition, and to 3 interventions - of which Brachytherapy is the first listed.
NCT03277469 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03277469 about?
NCT03277469 is a clinical study titled "Optimizing Brachytherapy Application and Delivery With MRI Guidance for Gynecologic Cancer". The aim of this study is to develop new tools using magnetic resonance imaging (MRI) that will improve the brachytherapy procedure and treatment for participants with gynecologic cancer.
What is the current status of trial NCT03277469?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 49 participants. The study started on 2017-11-13. Estimated completion is 2027-09-15.
What conditions does trial NCT03277469 study?
This clinical trial studies the following conditions: Gynecologic Cancer.
What interventions are being tested in trial NCT03277469?
The interventions under investigation include: Brachytherapy (RADIATION), MRI (DEVICE), MRI Tracker (DEVICE).
Who is sponsoring clinical trial NCT03277469?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03277469 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gynecologic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03277469's enrollment target sits among peer trials
49 34th of 55 higher than 22 of 55 other Gynecologic Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gynecologic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Prospective Evaluation of Pencil Beam Scanning Proton Therapy for Previously Irradiated Tumors
RECRUITING · NA
-
Chatbot to Maximize Hereditary Cancer Genetic Risk Assessment
RECRUITING · NA
-
BOLSTER: Learning New Skills to Thrive
RECRUITING · NA
-
A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer
RECRUITING · NA
-
Activity Coaching During Pelvic Radiation Therapy
RECRUITING · NA
-
Transcranial Magnetic Stimulation for Chemotherapy-Induced Peripheral Neuropathy in Breast and Gynecologic Cancer Survivors
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02704858 · 49 participants · Phase 1
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
- NCT03516708 · 49 participants · Phase 1
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
- NCT03692429 · 49 participants · Phase 1
alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
- NCT04329494 · 49 participants · Phase 1
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI